200 related articles for article (PubMed ID: 21165566)
1. Screening of novel immunostimulatory CpG ODNs and their anti-leukemic effects as immunoadjuvants of tumor vaccines in murine acute lymphoblastic leukemia.
Wang J; Zhang W; He A; Zhao W; Cao X
Oncol Rep; 2011 Feb; 25(2):519-29. PubMed ID: 21165566
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model.
Cho HC; Kim BH; Kim K; Park JY; Chang JH; Kim SK
Int Immunopharmacol; 2008 Oct; 8(10):1401-7. PubMed ID: 18687302
[TBL] [Abstract][Full Text] [Related]
4. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.
Carpentier AF; Chen L; Maltonti F; Delattre JY
Cancer Res; 1999 Nov; 59(21):5429-32. PubMed ID: 10554011
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis.
Sparwasser T; Hültner L; Koch ES; Luz A; Lipford GB; Wagner H
J Immunol; 1999 Feb; 162(4):2368-74. PubMed ID: 9973517
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of a dendritic cell vaccine for murine renal cell carcinoma by CpG oligonucleotides.
Chagnon F; Tanguay S; Ozdal OL; Guan M; Ozen ZZ; Ripeau JS; Chevrette M; Elhilali MM; Thompson-Snipes LA
Clin Cancer Res; 2005 Feb; 11(3):1302-11. PubMed ID: 15709202
[TBL] [Abstract][Full Text] [Related]
7. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
[TBL] [Abstract][Full Text] [Related]
8. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
[TBL] [Abstract][Full Text] [Related]
9. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
10. Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses.
Fabricius D; Breckerbohm L; Vollmer A; Queudeville M; Eckhoff SM; Fulda S; Strauss G; Debatin KM; Jahrsdörfer B; Meyer LH
Leukemia; 2011 Jul; 25(7):1111-21. PubMed ID: 21527935
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
[TBL] [Abstract][Full Text] [Related]
12. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis.
Xiong Z; Gharagozlou S; Vengco I; Chen W; Ohlfest JR
Clin Cancer Res; 2008 Sep; 14(17):5484-93. PubMed ID: 18765540
[TBL] [Abstract][Full Text] [Related]
13. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
14. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.
Seif AE; Barrett DM; Milone M; Brown VI; Grupp SA; Reid GS
Blood; 2009 Sep; 114(12):2459-66. PubMed ID: 19636062
[TBL] [Abstract][Full Text] [Related]
15. Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.
Barrier M; Lacroix-Lamandé S; Mancassola R; Auray G; Bernardet N; Chaussé AM; Uematsu S; Akira S; Laurent F
J Infect Dis; 2006 May; 193(10):1400-7. PubMed ID: 16619188
[TBL] [Abstract][Full Text] [Related]
16. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA.
Ballas ZK; Rasmussen WL; Krieg AM
J Immunol; 1996 Sep; 157(5):1840-5. PubMed ID: 8757300
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of CpG oligonucleotides on human neuroblastoma xenografts in nude mice].
Yao QH; Tang YJ; Gao FH; Tang JY
Ai Zheng; 2009 Apr; 28(4):344-9. PubMed ID: 19622291
[TBL] [Abstract][Full Text] [Related]
18. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen.
Baral RN; Saha A; Chatterjee S; Foon KA; Krieg A; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2003 May; 52(5):317-27. PubMed ID: 12700947
[TBL] [Abstract][Full Text] [Related]
20. CpG oligonucleotides for immunotherapeutic treatment of neuroblastoma.
Miles SA; Sandler AD
Adv Drug Deliv Rev; 2009 Mar; 61(3):275-82. PubMed ID: 19186194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]